Esperion Therapeutics Q4 revenue jumps 144% on US product strength

Overview

• Biopharmaceutical firm's Q4 total revenue grew 144% yr/yr to $168.4 mln

• Net income for Q4 missed analyst expectations

• Company to acquire Corstasis Therapeutics to expand cardiovascular franchise

Outlook

• Esperion expects 2026 operating expenses between $225 mln and $255 mln

Result Drivers

• U.S. PRODUCT REVENUE - Q4 U.S. net product revenue grew 38% y/y to $43.7 mln, driven by increased prescription growth and market access for bempedoic acid franchise

• COLLABORATION REVENUE - Q4 collaboration revenue increased 232% y/y, driven by a $90 mln payment from Otsuka for regulatory approval and favorable NHI Price listing

• GLOBAL EXPANSION - Esperion's global expansion strategy accelerated with regulatory approvals and market launches, contributing to revenue growth

Company press release: ID:nGNX1vGRQW

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Esperion Therapeutics Inc is $5.00, about 64.5% above its March 9 closing price of $3.04

• The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 144 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.